Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2287]

Front-line osimertinib significantly lengthens overall survival in EGFR...

Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta...

Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC ( Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, USA )

Comment: Front-line osimertinib significantly lengthens overall survival in...

Dr Marina Garassino - National Tumour Institute, Milan, Italy

Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC ( Dr Marina Garassino - National Tumour Institute, Milan, Italy )

A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple...

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

Comparative effectiveness of lenalidomide, bortezomib, and their combinations...

Dr Peter Barth - Rhode Island Hospital, Philadelphia, USA

Comparative effectiveness of lenalidomide, bortezomib, and their combinations for elderly myeloma patients ( Dr Peter Barth - Rhode Island Hospital, Philadelphia, USA )

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma

Prof Xavier Leleu - CHU la Miletrie, Poitiers, France

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )

Improved outcomes from quadruplet KCRD induction in newly diagnosed myeloma...

Dr Charlotte Pawlyn - Royal Marsden Hospital, London, UK

Improved outcomes from quadruplet KCRD induction in newly diagnosed myeloma patients ( Dr Charlotte Pawlyn - Royal Marsden Hospital, London, UK )

HORIZON: Melflufen in high risk relapsed refractory multiple myeloma patients...

Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA

$HORIZON: Melflufen in high risk relapsed refractory multiple myeloma patients with extramedullary disease ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )$

Iberdomide in combination with dexamethasone for multiple myeloma

Prof Sagar Lonial - Winship Cancer Institute, Atlanta, USA

Iberdomide in combination with dexamethasone for multiple myeloma ( Prof Sagar Lonial - Winship Cancer Institute, Atlanta, USA )

First results of the GMMG-CONCEPT trial for multiple myeloma

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

First results of the GMMG-CONCEPT trial for multiple myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )

PLEIADES: Daratumumab combinations for multiple myeloma

Dr Ajai Chari - Mount Sinai, New York City, USA

PLEIADES: Daratumumab combinations for multiple myeloma ( Dr Ajai Chari - Mount Sinai, New York City, USA )

Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory...

Dr James Berenson - Oncotherapeutics, West Hollywood, USA

$Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )$

Treatment options for high risk relapsed/refractory multiple myeloma

Dr James Berenson - Oncotherapeutics, West Hollywood, USA

$Treatment options for high risk relapsed/refractory multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )$

More from ecancer